Key result
Proteomic technologies, including mass spectrometry and gene expression library screening, offer distinct advantages and limitations for identifying autoantibody targets in neuroimmunological disorders.
Why the study?
A sound knowledge of the advantages and limitations of each proteomic technique is required to select the optimal methodology for antigen identification in neuroimmunological disorders.
Understanding the advantages and limitations of different proteomic technologies is essential for selecting the optimal methodology for antigen identification in neuroimmunological disorders.
Answers are grounded in this paper and cite their sources.
Requires case-by-case proteomic method selection for antigen identification; leaves open optimal standardized approaches in neuroimmunology.
Autoantibodies have been identified as key players in several neuroimmunological disorders such as autoimmune encephalitis, CNS demyelinating diseases, neuropathies, and neuromuscular junction disorders. Recent advances of proteomic technologies enable scientists to determine the target protein of autoantibodies. These methods are divided into three categories, namely, (1) mass spectrometry (MS)‐based method, (2) gene expression library screening, and (3) protein microarray. MS‐based methods can analyze posttranslationally modified proteins or conformational proteins, while gene expression library screening cannot. However, in MS‐based methods, protein‐abundant bias could prevent the identification of the target protein, and DNA sequencing could be more easily performed than MS‐based methods. Therefore, a sound knowledge of the advantages and limitations of each technique is required for selection of the optimal methodology for antigen identification in neuroimmunological disorders.
No takes yet. Share an insight, caveat, or question.
Sawai et al. (2021) conducted a review in Neuroimmunological disorders. Proteomic technologies (mass spectrometry, gene expression library screening, protein microarray) was evaluated. Proteomic technologies, including mass spectrometry and gene expression library screening, offer distinct advantages and limitations for identifying autoantibody targets in neuroimmunological disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: